Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384784 · ClinicalTrials.gov registry record · Phase 2
Effect of Galantamine on Inflammation and Cognition
A Phase 2 study of HIV Associated Cognitive Motor Complex, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT03384784 is a Phase 2 study of HIV Associated Cognitive Motor Complex that has completed, run by University of Pennsylvania. The registered enrollment target is 63 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03384784, a Phase 2 study of HIV Associated Cognitive Motor Complex, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). Outcomes are monocyte/macrophage and T cell activation and neurocognitive performance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Galantamine
Study Locations (1)
Pennsylvania
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03384784
The ClinicalTrials.gov registry entry for NCT03384784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Associated Cognitive Motor Complex appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03384784 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03384784 about?
NCT03384784 is a clinical study titled "Effect of Galantamine on Inflammation and Cognition". This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout,...
What is the current status of trial NCT03384784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2017-10-30. Estimated completion is 2022-05-31.
What conditions does trial NCT03384784 study?
This clinical trial studies the following conditions: HIV Associated Cognitive Motor Complex.
What interventions are being tested in trial NCT03384784?
The interventions under investigation include: Placebo (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT03384784?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03384784 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Associated Cognitive Motor Complex
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.